

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).

I hereby appoint:



Practitioners associated with the Customer Number:

25885

OR



Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

| Name | Registration Number | Name | Registration Number |
|------|---------------------|------|---------------------|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:



The address associated with Customer Number:

25885

OR



Firm or Individual Name

Address

City

State

Zip

Country

Telephone

Email


Assignee Name and Address:

IMCLONE SYSTEMS CORPORATION
180 VARICK STREET, 6TH FLOOR
NEW YORK, NEW YORK 10014

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

| | | | |
|-----------|---|-----------|--------------|
| Signature |  | Date | 2-26-2009 |
| Name | Douglas K. Norman | Telephone | 317-276-2958 |
| Title | Vice President, General Patent Counsel | | |

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

CERTIFICATE UNDER 37 CFR 3.73(b)

First Applicant: Harlan W. Waksal

Serial No.: 09/996,954

Application Date: 30 November 2001

US Nat'l Entry Date:

Entitled: TREATMENT OF REFRACTORY HUMAN TUMORS WITH EPIDERMAL GROWTH
FACTOR RECEPTOR ANTAGONISTS

ImClone Systems Incorporated, a Delaware Corporation

(Name of Assignee)

(Type of Assignee, e.g. corporation, partnership, university, government agency, etc.)

certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of
either:

A. ☒ An assignment from the inventor(s) of the patent application identified above.

☒ The assignment was recorded in the Patent and Trademark Office at Reel 010153, Frame 0220.

☐ The assignment is being submitted separately for recordation; a copy of this assignment is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application identified above, to the current assignee as shown
below:

1. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on
information and belief are believed to be true; and further, that these statements are made with the knowledge that willful
false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the
United States Code, and that such willful false statements may jeopardize the validity of the application or any patent
issuing thereon.

April 2, 2009
Date

/Gregory A. Cox/
Gregory A. Cox
Patent Counsel

Delegation of Authority Concerning
Certain Patent Matters

Pursuant to the authority granted to me by Gino Santini, President, ImClone Systems Corp., in a document dated February 3, 2009 (a copy which is attached as Appendix A), I delegate to each of the following persons:

| | | | |
|------------------------|--------|-------------------------|--------|
| Arvie J. Anderson | 45,263 | Paul J. Koivuniemi | 31,533 |
| Lynn D. Apelgren | 45,341 | Robert E. Lee | 27,919 |
| Robert A. Armitage | 27,417 | James P. Leeds | 35,241 |
| Brian P. Barrett | 39,597 | Nelsen L. Lentz | 38,537 |
| Gary M. Birch | 48,881 | Alejandro Martinez | 58,163 |
| Steven P. Caltrider | 36,467 | Elizabeth A. McGraw | 44,646 |
| Paul R. Cantrell | 36,470 | James B. Myers | 42,021 |
| John A. Cleveland, Jr. | 50,697 | Douglas K. Norman | 33,267 |
| Charles E. Cohen | 34,565 | Arleen Palmberg | 40,422 |
| Tonya L. Combs | 57,909 | Thomas G. Plant | 35,784 |
| Donald L. Corneglio | 30,741 | Edward J. Prein | 37,212 |
| Gregory A. Cox | 47,504 | Robert L. Sharp | 45,609 |
| Paula K. Davis | 47,517 | Mark J. Stewart | 43,936 |
| John C. Demeter | 30,167 | Robert D. Titus | 40,206 |
| Manisha A. Desai | 43,585 | R. Craig Tucker | 45,165 |
| Ted Ebersole | 51,641 | Tina M. Tucker | 47,145 |
| Paul J. Gaylo | 36,808 | MaCharri Vorndran-Jones | 36,711 |
| Caren D. Geppert | 54,117 | Gilbert T. Voy | 43,972 |
| Francis O. Ginah | 44,712 | Lawrence T. Welch | 29,487 |
| Amy E. Hamilton | 33,894 | Alexander Wilson | 45,782 |
| Averie Hason | 57,722 | Mark A. Winter | 53,782 |
| Danica Hostettler | 51,820 | MaryAnn Wiskerchen | 45,511 |
| Thomas E. Jackson | 33,064 | Dan L. Wood | 48,613 |
| Sanjay M. Jivraj | 61,806 | Nicole Woods | 56,579 |
| Gerald P. Keleher | 43,707 | Congping Xie | 57,817 |
| James J. Kelley | 41,888 | | |

all of whom are registered to practice before the United States Patent and Trademark Office and are employees of Eli Lilly and Company, the authority to approve and execute for and on behalf of the Company, documents in connection with patent matters relating to:

- (i) the institution, prosecution, and completion of proceedings directed towards the issuance of patents;
- (ii) the amendment, restriction, renewal, reissue, revival, maintenance, restoration, cancellation, extension, and abandonment of patents and of applications for patents;
- (iii) the institution, prosecution, and termination of proceedings of interference, opposition, revocation, and nullification, including the filing of preliminary statements, concessions of priority, disclaimers, abandonments of contests, and abandonments of the invention;


(iv) the settlement of patent proceedings of interference, opposition, revocation, and nullification, subject to prior approval by the Senior Vice President and General Counsel of the Company;

(v) the filing of statutory disclaimers;

(vi) the institution, prosecution, and termination of appellate proceedings; and

(vii) the granting and the revocation of powers of attorney in connection with any of the foregoing, except there shall be no authority to revoke any power of attorney held by the Vice President and General Patent Counsel, Lilly Research Laboratories (a division of the Company).

Dated: 6 February 2009



Douglas K. Norman
Vice President and General Patent Counsel


**Delegation of Authority Concerning
Certain Patent Matters**

On behalf of ImClone Systems Corporation (ImClone), a Delaware corporation with a principal place of business at 180 Varick Street, New York City, New York, a wholly-owned subsidiary of Eli Lilly and Company, an Indiana corporation with a principal place of business at Lilly Corporate Center, Indianapolis Indiana 46285, I delegate to Douglas K. Norman, Vice President and General Patent Counsel of Eli Lilly and Company; Amy E. Hamilton, Deputy General Patent Counsel of Eli Lilly and Company; and James J. Kelley, Assistant General Patent Counsel of Eli Lilly and Company:

Authority to approve and execute for and on behalf of ImClone, documents in connection with patent matters relating to:

- (i) the institution, prosecution, and completion of proceedings directed towards the issuance of patents;
- (ii) the amendment, restriction, renewal, reissue, revival, maintenance, restoration, cancellation, extension, and abandonment of patents and of applications for patents;
- (iii) the institution, prosecution, and termination of proceedings of interference, opposition, revocation, and nullification, including the filing of preliminary statements, concessions of priority, disclaimers, abandonments of the contents, and abandonments of the invention;
- (iv) the settlement of patent proceedings of interference, opposition, revocation, and nullification, subject to prior approval by the Senior Vice President and General Counsel of Eli Lilly and Company;
- (v) the filing of statutory disclaimers;
- (vi) the institution, prosecution, and termination of appellate proceedings; and
- (vii) the granting and the revocation of powers of attorney in connection with any of the foregoing.

Dated: 2/3/09



Gino Santini
President, ImClone Systems Corp.